Peptides in the era of biotech

Chimeric antigen receptor (CAR)-T cell therapy is a revolutionary method that has emerged as a cutting-edge cancer treatment, harnessing the patient's T cells to bolster their immune system's anti-cancer capabilities. Traditionally, CAR-T cell production has relied on viral vectors, which present safety concerns, high costs, and production challenges. The investigation and development of alternative gene delivery systems are unlocking new possibilities.

Advanced Therapy Medicinal Products (ATMPs) are revolutionizing the treatment of a wide range of severe diseases. Their potential to deliver long-lasting or even curative effects places them at the forefront of biomedical innovation. However, despite their clinical promise, the successful development and widespread adoption of ATMPs face two critical hurdles: high manufacturing costs and market access specificities.